11 Jun Berberine in the Age of Ozempic: Discussing What the RCT Evidence Shows
Supplement Notice: Berberine is a dietary supplement and is not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, or prevent any disease. It is not a substitute for prescription medications including metformin, semaglutide (Ozempic/Wegovy), or any other FDA-approved therapy. Berberine can interact with prescription medications including warfarin, cyclosporine, and metformin. Do not use berberine as a replacement for prescribed treatment without consulting your physician. Always seek the advice of a qualified healthcare provider before starting any supplement regimen.
Few supplements have had a more dramatic cultural moment than berberine. Once confined to the shelves of specialty health stores and the protocols of integrative medicine practitioners, berberine has become something of a phenomenon — propelled partly by social media comparisons to semaglutide (sold as Ozempic and Wegovy), a prescription GLP-1 receptor agonist that has transformed the treatment of type 2 diabetes and obesity. The comparison has a surface-level appeal. Both compounds influence metabolic pathways involved in blood sugar regulation. Both are discussed in the context of weight management. Berberine is a fraction of the cost, available without a prescription, and marketed across wellness channels as a "natural" alternative. The shorthand — "nature's Ozempic" — spread quickly and widely. The problem is that shorthand compresses a complicated evidence picture into a slogan. What the randomized controlled trial (RCT) evidence on berberine actually shows is more interesting — and more nuanced — than either its most enthusiastic proponents or its dismissers tend to acknowledge.